Pharmacogenomic and structural analysis of constitutive G protein-coupled receptor activity

Annual Review of Pharmacology and Toxicology

Volumn 47, Issue , 2007, Pages 53-87

  Smit, Martine J ^a   Vischer, Henry F ^a   Bakker, Remko A ^a   Jongejan, Aldo ^a   Timmerman, Henk ^a   Pardo, Leonardo ^b   Leurs, Rob ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Constitutive activity; inverse agonism; Receptor motifs; Receptor structure

Indexed keywords

CALCIUM SENSING RECEPTOR; CETIRIZINE; CIMETIDINE; FOLLITROPIN RECEPTOR; FRIZZLED PROTEIN; G PROTEIN COUPLED RECEPTOR; GLYCOPROTEIN; GROWTH HORMONE RECEPTOR; HALOPERIDOL; LOSARTAN; LUTEINIZING HORMONE RECEPTOR; MELANOCORTIN RECEPTOR; METOPROLOL; MONTELUKAST; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE RELATED PROTEIN RECEPTOR; RECEPTOR SUBTYPE; RECEPTOR SUBUNIT; RHODOPSIN; THYROTROPIN RECEPTOR;

BINDING SITE; GENETIC CODE; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR CLONING; MOLECULAR GENETICS; NONHUMAN; PHARMACOGENOMICS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

HUMANS; MODELS, MOLECULAR; PHARMACOGENETICS; POINT MUTATION; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 33847081648     PISSN: 03621642     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.pharmtox.47.120505.105126     Document Type: Review

References (200)

1. Langley JN. 1878. On the physiology of the salivary secretion. Part II. On the mutual antagonism of atropin and pilocarpin, having especial reference to their relations in the submaxillary gland of the cat. J. Physiol. 1:339-60
2. Ehrlich P. 1909. Über den jetzigen Stand der Chemotherapie. Ber. Dtsch. Chem. Ges. 42:17-47
3. Fischer E. 1894. Einfluss der Configuration auf die Wirkung der Enzyme. Ber. Dtsch. Chem. Ges. 27:2985-33
4. Clark AJ. 1933. The Mode of Action of Drugs on Cells. London: Edward Arnold
5. Clark AJ. 1937. General Pharmacology: Heffter's Handbuch der Experimentellen Pharmacology. Berlin: Ergband 4, Springer
6. Ariens EJ. 1964. Molecular Pharmacology. New York: Academic
7. Stephenson RP. 1956. A modification of receptor theory. Br. J. Pharmacol. 11:379-93
8. Furchgott RF. 1966. The use of b-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. In Advances in Drug Research, ed. NJ Harper, AB Simmonds, pp. 21-55. New York: Academic
9. Furchgott RF. 1972. The classification of adrenoreceptors (adrenergic receptors): an evaluation from the standpoint of receptor theory. In Handbook of Experimental Pharmacology, ed. H Blaschko, E Muscholl, pp. 283-335. Berlin: Springer-Verlag
10. Ariens EJ, Simonis AM. 1967. Cholinergic and anticholinergic drugs, do they act on common receptors? Ann. N.Y. Acad. Sci. 144:842-69
11. Nauta WT, Rekker RF, Harms AF. 1968. Diarylcarbinol ethers: structure activity relationships. A physico-chemical approach. In Physico-Chemical Aspects of Drug Action, ed. EJ Ariens, pp. 305-25. Oxford: Pergamon
12. Dixon RAF, Kobilka BK, Strader DJ, Benovic JL, Dohlman HG, et al. 1986. Cloning of the gene and cDNA for mammalian b-adrenergic receptor and homology with rhodopsin. Nature 321:75-79
13. Kristiansen K. 2004. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol. Ther. 103:21-80
14. Fredriksson R, Lagerstrom MC, Lundin LG, Schioth HB. 2003. The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 63:1256-72
15. Horn F, Bettler E, Oliveira L, Campagne F, Cohen FE, Vriend G. 2003. GPCRDB information system for G protein-coupled receptors. Nucleic. Acids Res. 31:294-97
16. Foord SM, Bonner TI, Neubig RR, Rosser EM, Pin JP, et al. 2005. International Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol. Rev. 57:279-88
17. Milligan G. 2003. Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol. Pharmacol. 64:1271-76
18. Costa T, Cotecchia S. 2005. Historical review: negative efficacy and the constitutive activity of G-protein-coupled receptors. Trends Pharmacol. Sci. 26:618-24
19. Seifert R, Wenzel-Seifert K. 2002. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch. Pharmacol. 366:381-416
20. Bond RA, Ijzerman AP. 2006. Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol. Sci. 27:92-96
21. Costa T, Herz A. 1989. Antagonists with negative intrinsic activity at d opioid receptors coupled to GTP-binding proteins. Proc. Natl. Acad. Sci. USA 86:7321-25
22. de Ligt RA, Kourounakis I, Ijzerman AP. 2000. Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br. J. Pharmacol. 130:1-12
23. Kenakin T. 2003. Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol. Sci. 24:346-54
24. Kenakin T. 2001. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J. 15:598-611
25. 2-adrenergic receptor. J. Biol. Chem. 268:4625-36
26. Vischer HF, Leurs R, Smit MJ. 2006. HCMV-encoded G-protein-coupled receptors as constitutively active modulators of cellular signaling networks. Trends Pharmacol. Sci. 27:56-63
27. Sodhi A, Montaner S, Gutkind JS. 2004. Viral hijacking of G-protein-coupled-receptor signaling networks. Nat. Rev. Mol. Cell Biol. 5:998-1012
28. Wieland K, Bongers G, Yamamoto Y, Hashimoto T, Yamatodani A, et al. 2001. Constitutive activity of histamine H(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists. J. Pharmacol. Exp. Ther. 299:908-14
29. Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, et al. 2000. High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 408:860-64
30. Adan RA. 2006. Constitutive receptor activity series: endogenous inverse agonists and constitutive receptor activity in the melanocortin system. Trends Pharmacol. Sci. 27:183-86
31. Rossier O, Abuin L, Fanelli F, Leonardi A, Cotecchia S. 1999. Inverse agonism and neutral antagonism at alpha(1a)- and alpha(1b)-adrenergic receptor subtypes. Mol. Pharmacol. 56:858-66
32. Takezako T, Gogonea C, Saad Y, Noda K, Karnik SS. 2004. "Network leaning" as a mechanism of insurmountable antagonism of the angiotensin II type 1 receptor by nonpeptide antagonists. J. Biol. Chem. 279:15248-57
33. Miserey-Lenkei S, Parnot C, Bardin S, Corvol P, Clauser E. 2002. Constitutive internalization of constitutively active angiotensin II AT(1A) receptor mutants is blocked by inverse agonists. J. Biol. Chem. 277:5891-901
34. Hall DA, Strange PG. 1997. Evidence that antipsychotic drugs are inverse agonists at D-2 dopamine receptors. Br. J. Pharmacol. 121:731-36
35. Dupre DJ, Le Gouill C, Gingras D, Rola-Pleszczynski M, Stankova J. 2004. Inverse agonist activity of selected ligands of the cysteinyl-leukotriene receptor 1. J. Pharmacol. Exp. Ther. 309:102-8
36. Bakker RA, Wieland K, Timmerman H, Leurs R. 2000. Constitutive activity of the histamine H(1) receptor reveals inverse agonism of histamine H(1) receptor antagonists. Eur. J. Pharmacol. 387:R5-7
37. 2 receptors. Proc. Natl. Acad. Sci. USA 93:6802-7
38. Rauser L, Savage JE, Meltzer HY, Roth BL. 2001. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J. Pharmacol. Exp. Ther. 299:83-89
39. Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, et al. 2001. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J. Pharmacol. Exp. Ther. 299:268-76
40. Maack C, Cremers B, Flesch M, Hoper A, Sudkamp M, Bohm M. 2000. Different intrinsic activities of bucindolol, carvedilol and metoprolol in human failing myocardium. Br. J. Pharmacol. 130:1131-39
41. Milligan G, Bond RA. 1997. Inverse agonism and the regulation of receptor number. Trends Pharmacol. Sci. 18:468-74
42. Leurs R, Smit MJ, Alewijnse AE, Timmerman H. 1998. Agonist-independent regulation of constitutively active G-protein-coupled receptors. Trends Biochem. Sci. 23:418-22
43. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, et al. 2000. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289:739-45
44. Li J, Edwards PC, Burghammer M, Villa C, Schertler GF. 2004. Structure of bovine rhodopsin in a trigonal crystal form. J. Mol. Biol. 343:1409-38
45. Mirzadegan T, Benko G, Filipek S, Palczewski K. 2003. Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. Biochemistry 42:2759-67
46. Ballesteros JA, Weinstein H. 1995. Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods Neurosci. 25:366-428
47. Farrens DL, Altenbach C, Yang K, Hubbell WL, Khorana HG. 1996. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 274:768-70
48. Ballesteros JA, Jensen AD, Liapakis G, Rasmussen SG, Shi L, et al. 2001. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J. Biol. Chem. 276:29171-77
49. Montanelli L, van Durme JJ, Smits G, Bonomi M, Rodien P, et al. 2004. Modulation of ligand selectivity associated with activation of the transmembrane region of the human follitropin receptor. Mol. Endocrinol. 18:2061-73
50. Kim JM, Altenbach C, Thurmond RL, Khorana HG, Hubbell WL. 1997. Structure and function in rhodopsin: rhodopsin mutants with a neutral amino acid at E134 have a partially activated conformation in the dark state. Proc. Natl. Acad. Sci. USA 94:14273-78
51. Alewijnse AE, Timmerman H, Jacobs EH, Smit MJ, Roovers E, et al. 2000. The effect of mutations in the DRY motif on the constitutive activity and structural instability of the histamine H(2) receptor. Mol. Pharmacol. 57:890-98
52. 1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation. EMBO J. 15:3566-78
53. Ballesteros J, Kitanovic S, Guarnieri F, Davies P, Fromme BJ, et al. 1998. Functional microdomains in G-protein-coupled receptors. The conserved arginine-cage motif in the gonadotropin-releasing hormone receptor. J. Biol. Chem. 273:10445-53
54. Laue L, Chan WY, Hsueh AJ, Kudo M, Hsu SY, et al. 1995. Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty. Proc. Natl. Acad. Sci. USA 92:1906-10
55. Baranski TJ, Herzmark P, Lichtarge O, Gerber BO, Trueheart J, et al. 1999. C5a receptor activation. Genetic identification of critical residues in four transmembrane helices. J. Biol. Chem. 274:15757-65
56. Ringkananont U, Van Durme J, Montanelli L, Ugrasbul F, Yu YM, et al. 2006. Repulsive separation of the cytoplasmic ends of transmembrane helices 3 and 6 is linked to receptor activation in a novel thyrotropin receptor mutant (M626I). Mol. Endocrinol. 20:893-903
57. Lu ZL, Saldanha JW, Hulme EC. 2002. Seven-transmembrane receptors: crystals clarify. Trends Pharmacol. Sci. 23:140-46
58. Fritze O, Filipek S, Kuksa V, Palczewski K, Hofmann KP, Ernst OP. 2003. Role of the conserved NPxxY(x)5,6F motif in the rhodopsin ground state and during activation. Proc. Natl. Acad. Sci. USA 100:2290-95
59. Prioleau C, Visiers I, Ebersole BJ, Weinstein H, Sealfon SC. 2002. Conserved helix 7 tyrosine acts as a multistate conformational switch in the 5HT2C receptor. Identification of a novel "locked-on" phenotype and double revertant mutations. J. Biol. Chem. 277:36577-84
60. Verzijl D, Pardo L, Van Dijk M, Gruijthuijsen YK, Jongejan A, et al. 2006. Helix 8 of the viral chemokine receptor ORF74 directs chemokine binding. J. Biol. Chem. doi:10.1074/jbc.M606877200
61. Govaerts C, Lefort A, Costagliola S, Wodak SJ, Ballesteros JA, et al. 2001. A conserved Asn in transmembrane helix 7 is an on/off switch in the activation of the thyrotropin receptor. J. Biol. Chem. 276:22991-99
62. Urizar E, Claeysen S, Deupi X, Govaerts C, Costagliola S, et al. 2005. An activation switch in the rhodopsin family of G protein-coupled receptors: the thyrotropin receptor. J. Biol. Chem. 280:17135-41
63. Okada T, Fujiyoshi Y, Silow M, Navarro J, Landau EM, Shichida Y. 2002. Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc. Natl. Acad. Sci. USA 99:5982-87
64. Deleted in proof
65. Madabushi S, Gross AK, Philippi A, Meng EC, Wensel TG, Lichtarge O. 2004. Evolutionary trace of G protein-coupled receptors reveals clusters of residues that determine global and class-specific functions. J. Biol. Chem. 279:8126-32
66. Han M, Lin SW, Minkova M, Smith SO, Sakmar TP. 1996. Functional interaction of transmembrane helices 3 and 6 in rhodopsin-replacement of phenylalanine 261 by alanine causes reversion of phenotype of a glycine 121 replacement mutant. J. Biol. Chem. 271:32337-42
67. Shapiro DA, Kristiansen K, Weiner DM, Kroeze WK, Roth BL. 2002. Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. J. Biol. Chem. 277:11441-49
68. Klco JM, Wiegand CB, Narzinski K, Baranski TJ. 2005. Essential role for the second extracellular loop in C5a receptor activation. Nat. Struct. Mol. Biol. 12:320-26
69. Ruprecht JJ, Mielke T, Vogel R, Villa C, Schertler GF. 2004. Electron crystallography reveals the structure of metarhodopsin I. EMBO J. 23:3609-20
70. Lin SW, Sakmar TP. 1996. Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. Biochemistry 35:11149-59
71. Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, Javitch JA. 2002. Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J. Biol. Chem. 277:40989-96
72. Jongejan A, Bruysters M, Ballesteros JA, Haaksma E, Bakker RA, et al. 2005. Linking agonist binding to histamine H1 receptor activation. Nat. Chem. Biol. 1:98-103
73. McAllister SD, Hurst DP, Barnett-Norris J, Lynch D, Reggio PH, Abood ME. 2004. Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J. Biol. Chem. 279:48024-37 74. Xu W, Campillo M, Pardo L, Kim de Riel J, Liu-Chen LY. 2005. The seventh transmembrane domains of the delta and kappa opioid receptors have different accessibility patterns and interhelical interactions. Biochemistry 44:16014-25
74. Auger-Messier M, Clement M, Lanctot PM, Leclerc PC, Leduc R, et al. 2003. The constitutively active N111G-AT1 receptor for angiotensin II maintains a high affinity conformation despite being uncoupled from its cognate G protein Gq/11alpha. Endocrinology 144:5277-84
75. Shi L, Javitch JA. 2002. The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu. Rev. Pharmacol. Toxicol. 42:437-67
76. Lopez-Rodriguez ML, Morcillo MJ, Fernandez E, Benhamu B, Tejada I, et al. 2005. Synthesis and structure-activity relationships of a new model of arylpiperazines. 8. Computational simulation of ligand-receptor interaction of 5-HT(1A)R agonists with selectivity over alpha 1-adrenoceptors. J. Med. Chem. 48:2548-58
77. Bownds D. 1967. Site of attachment of retinal in rhodopsin. Nature 216:1178-81
78. Sakmar TP, Franke RR, Khorana HG. 1989. Glutamic acid-113 serves as the retinylidene Schiff base counterion in bovine rhodopsin. Proc. Natl. Acad. Sci. USA 86:8309-13
79. Okada T, Ernst OP, Palczewski K, Hofmann KP. 2001. Activation of rhodopsin: new insights from structural and biochemical studies. Trends Biochem. Sci. 26:318-24
80. Robinson PR, Cohen GB, Zhukovsky EA, Oprian DD. 1992. Constitutively active mutants of rhodopsin. Neuron 9:719-25
81. Kim JM, Altenbach C, Kono M, Oprian DD, Hubbell WL, Khorana HG. 2004. Structural origins of constitutive activation in rhodopsin: role of the K296/E113 salt bridge. Proc. Natl. Acad. Sci. USA 101:12508-13
82. Keen TJ, Inglehearn CF, Lester DH, Bashir R, Jay M, et al. 1991. Autosomal dominant retinitis pigmentosa: four new mutations in rhodopsin, one of them in the retinal attachment site. Genomics 11:199-205
83. Lem J, Fain GL. 2004. Constitutive opsin signaling: night blindness or retinal degeneration? Trends Mol. Med. 10:150-57
84. Gross AK, Rao VR, Oprian DD. 2003. Characterization of rhodopsin congenital night blindness mutant T94I. Biochemistry 42:2009-15
85. Gross AK, Xie G, Oprian DD. 2003. Slow binding of retinal to rhodopsin mutants G90D and T94D. Biochemistry 42:2002-8
86. Vassart G, Pardo L, Costagliola S. 2004. A molecular dissection of the glycoprotein hormone receptors. Trends Biochem. Sci. 29:119-26
87. Osuga Y, Kudo M, Kaipia A, Kobilka B, Hsueh AJ. 1997. Derivation of functional antagonists using N-terminal extracellular domain of gonadotropin and thyrotropin receptors. Mol. Endocrinol. 11:1659-68
88. Fan QR, Hendrickson WA. 2005. Structure of human follicle-stimulating hormone in complex with its receptor. Nature 433:269-77
89. Vischer HF, Granneman JC, Noordam MJ, Mosselman S, Bogerd J. 2003. Ligand selectivity of gonadotropin receptors. Role of the beta-strands of extracellular leucine-rich repeats 3 and 6 of the human luteinizing hormone receptor. J. Biol. Chem. 278:15505-13
90. Smits G, Campillo M, Govaerts C, Janssens V, Richter C, et al. 2003. Glycoprotein hormone receptors: determinants in leucine-rich repeats responsible for ligand specificity. EMBO J. 22:2692-703
91. Van Durme J, Horn F, Costagliola S, Vriend G, Vassart G. 2006. GRIS: glycoprotein-hormone receptor information system. Mol. Endocrinol. 20:2247-55
92. De Felice M, Postiglione MP, Di Lauro R. 2004. Minireview: thyrotropin receptor signaling in development and differentiation of the thyroid gland: insights from mouse models and human diseases. Endocrinology 145:4062-67
93. Corvilain B, Van Sande J, Dumont JE, Vassart G. 2001. Somatic and germline mutations of the TSH receptor and thyroid diseases. Clin. Endocrinol. 55:143-58
94. Zhang M, Tong KP, Fremont V, Chen J, Narayan P, et al. 2000. The extracellular domain suppresses constitutive activity of the transmembrane domain of the human TSH receptor: implications for hormone-receptor interaction and antagonist design. Endocrinology 141:3514-17
95. Vlaeminck-Guillem V, Ho SC, Rodien P, Vassart G, Costagliola S. 2002. Activation of the cAMP pathway by the TSH receptor involves switching of the ectodomain from a tethered inverse agonist to an agonist. Mol. Endocrinol. 16:736-46
96. Themmen APN, Huhtaniemi IT. 2000. Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr. Rev. 21:551-83
97. Delemarre-van de Waal HA. 2002. Regulation of puberty. Best Pract. Res. Clin. Endocrinol. Metab. 16:1-12
98. Themmen AP. 2005. An update of the pathophysiology of human gonadotrophin subunit and receptor gene mutations and polymorphisms. Reproduction 130:263-74
99. Shinozaki H, Fanelli F, Liu X, Jaquette J, Nakamura K, Segaloff DL. 2001. Pleiotropic effects of substitutions of a highly conserved leucine in transmembrane helix III of the human lutropin/choriogonadotropin receptor with respect to constitutive activation and hormone responsiveness. Mol. Endocrinol. 15:972-84
100. Zhang M, Mizrachi D, Fanelli F, Segaloff DL. 2005. The formation of a salt bridge between helices 3 and 6 is responsible for the constitutive activity and lack of hormone responsiveness of the naturally occurring L457R mutation of the human lutropin receptor. J. Biol. Chem. 280:26169-76
101. Nakabayashi K, Kudo M, Hsueh AJ, Maruo T. 2003. Activation of the luteinizing hormone receptor in the extracellular domain. Mol. Cell Endocrinol. 202:139-44
102. Nishi S, Nakabayashi K, Kobilka B, Hsueh AJ. 2002. The ectodomain of the luteinizing hormone receptor interacts with exoloop 2 to constrain the transmembrane region: studies using chimeric human and fly receptors. J. Biol. Chem. 277:3958-64
103. Nakabayashi K, Kudo M, Kobilka B, Hsueh AJ. 2000. Activation of the luteinizing hormone receptor following substitution of Ser-277 with selective hydrophobic residues in the ectodomain hinge region. J. Biol. Chem. 275:30264-71
104. Plant TM, Marshall GR. 2001. The functional significance of FSH in spermatogenesis and the control of its secretion in male primates. Endocr. Rev. 22:764-86
105. Gromoll J, Simoni M, Nieschlag E. 1996. An activating mutation of the follicle-stimulating hormone receptor autonomously sustains spermatogenesis in a hypophysectomized man. J. Clin. Endocrinol. Metab. 81:1367-70
106. Haywood M, Tymchenko N, Spaliviero J, Koch A, Jimenez M, et al. 2002. An activated human follicle-stimulating hormone (FSH) receptor stimulates FSH-like activity in gonadotropin-deficient transgenic mice. Mol. Endocrinol. 16:2582-91
107. Simoni M, Gromoll J, Nieschlag E. 1997. The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology. Endocr. Rev. 18:739-73
108. Allan CM, Garcia A, Spaliviero J, Jimenez M. 2006. Maintenance of spermatogenesis by the activated human (Asp567Gly) FSH receptor during testicular regression due to hormonal withdrawal. Biol. Reprod. 74:938-44
109. Macklon NS, Stouffer RL, Giudice LC, Fauser BC. 2006. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr. Rev. 27:170-207
110. Smits G, Olatunbosun O, Delbaere A, Pierson R, Vassart G, Costagliola S. 2003. Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. N. Engl. J. Med. 349:760-66
111. Montanelli L, Delbaere A, Di Carlo C, Nappi C, Smits G, et al. 2004. A mutation in the follicle-stimulating hormone receptor as a cause of familial spontaneous ovarian hyperstimulation syndrome. J. Clin. Endocrinol. Metab. 89:1255-58
112. Vasseur C, Rodien P, Beau I, Desroches A, Gerard C, et al. 2003. A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. N. Engl. J. Med. 349:753-59
113. De Leener A, Montanelli L, Van Durme J, Chae H, Smits G, et al. 2006. Presence and absence of follicle-stimulating hormone receptor mutations provide some insights into spontaneous ovarian hyperstimulation syndrome physiopathology. J. Clin. Endocrinol. Metab. 91:555-62
114. Kaiser UB. 2003. The pathogenesis of the ovarian hyperstimulation syndrome. N. Engl. J. Med. 349:729-32
115. Borgel K, Pohlenz J, Koch HG, Bramswig JH. 2005. Long-term carbimazole treatment of neonatal nonautoimmune hyperthyroidism due to a new activating TSH receptor gene mutation (Ala428Val). Horm. Res. 64:203-8
116. Soriano-Guillen L, Lahlou N, Chauvet G, Roger M, Chaussain JL, Carel JC. 2005. Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty. J. Clin. Endocrinol. Metab. 90:147-51
117. Reiter EO, Norjavaara E. 2005. Testotoxicosis: current viewpoint. Pediatr. Endocrinol. Rev. 3:77-86
118. Manivannan E, Prasanna S. 2005. First QSAR report on FSH receptor antagonistic activity: quantitative investigations on physico-chemical and structural features among 6-amino-4-phenyltetrahydroquinoline derivatives. Bioorg. Med. Chem. Lett. 15:4496-501
119. Wrobel J, Green D, Jetter J, Kao W, Rogers J, et al. 2002. Synthesis of (bis)sulfonic acid, (bis)benzamides as follicle-stimulating hormone (FSH) antagonists. Bioorg. Med. Chem. 10:639-56
120. van Straten NC, Schoonus-Gerritsma GG, van Someren RG, DraaijerJ, Adang AE, et al. 2002. The first orally active low molecular weight agonists for the LH receptor: thienopyr(im)idines with therapeutic potential for ovulation induction. Chembiochem 3:1023-26
121. van Straten NC, van Berkel TH, Demont DR, Karstens WJ, Merkx R, et al. 2005. Identification of substituted 6-amino-4-phenyltetrahydroquinoline derivatives: potent antagonists for the follicle-stimulating hormone receptor. J. Med. Chem. 48:1697-700
122. Guo T, Adang AE, Dolle RE, Dong G, Fitzpatrick D, et al. 2004. Small molecule biaryl FSH receptor agonists. Part 1: lead discovery via encoded combinatorial synthesis. Bioorg. Med. Chem. Lett. 14:1713-16
123. Arey BJ, Deecher DC, Shen ES, Stevis PE, Meade EHJ, et al. 2002. Identification and characterization of a selective, nonpeptide follicle-stimulating hormone receptor antagonist. Endocrinology 143:3822-29
124. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. 1999. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656-60
125. Hornby PJ. 2006. Designing spiegelmers to antagonise ghrelin. Gut 55:754-55
126. Grove KL, Cowley MA. 2005. Is ghrelin a signal for the development of metabolic systems? J. Clin. Invest. 115:3393-97
127. Holst B, Holliday ND, Bach A, Elling CE, Cox HM, Schwartz TW. 2004. Common structural basis for constitutive activity of the ghrelin receptor family. J. Biol. Chem. 279:53806-17
128. Pantel J, Legendre M, Cabrol S, Hilal L, Hajaji Y, et al. 2006. Loss of constitutive activity of the growth hormone secretagogue receptor in familial short stature. J. Clin. Invest. 116:760-68
129. Wang HJ, Geller F, Dempfle A, Schauble N, Friedel S, et al. 2004. Ghrelin receptor gene: identification of several sequence variants in extremely obese children and adolescents, healthy normal-weight and underweight students, and children with short normal stature. J. Clin. Endocrinol. Metab. 89:157-62
130. Holst B, Schwartz TW. 2006. Ghrelin receptor mutations-too little height and too much hunger. J. Clin. Invest. 116:637-41
131. Zhang JV, Ren PG, Avsian-Kretchmer O, Luo CW, Rauch R, et al. 2005. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 310:996-99
132. Graham A, Wakamatsu K, Hunt G, Ito S, Thody AJ. 1997. Agouti protein inhibits the production of eumelanin and phaeomelanin in the presence and absence of alpha-melanocyte stimulating hormone. Pigment. Cell Res. 10:298-303
133. Tao YX. 2006. Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications. Pharmacol. Ther. 111:949-73
134. Garcia-Borron JC, Sanchez-Laorden BL, Jimenez-Cervantes C. 2005. Melanocortin-1 receptor structure and functional regulation. Pigment. Cell Res. 18:393-410
135. Siegrist W, Drozdz R, Cotti R, Willard DH, Wilkison WO, Eberle AN. 1997. Interactions of alpha-melanotropin and agouti on B16 melanoma cells: evidence for inverse agonism of agouti. J. Recept. Signal. Transduct. Res. 17:75-98
136. Vergoni AV, Bertolini A, Guidetti G, Karefilakis V, Filaferro M, et al. 2000. Chronic melanocortin 4 receptor blockage causes obesity without influencing sexual behavior in male rats. J. Endocrinol. 166:419-26
137. Farooqi IS, Yeo GS, Keogh JM, Aminian S, Jebb SA, et al. 2000. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J. Clin. Invest. 106:271-79
138. Srinivasan S, Lubrano-Berthelier C, Govaerts C, Picard F, Santiago P, et al. 2004. Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J. Clin. Invest. 114:1158-64
139. Adan RA, Kas MJ. 2003. Inverse agonism gains weight. Trends Pharmacol. Sci. 24:315-21
140. Nicholson JR, Kohler G, Schaerer F, Senn C, Weyermann P, Hofbauer KG. 2006. Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice. J. Pharmacol. Exp. Ther. 317:771-77
141. Tao YX, Segaloff DL. 2005. Functional analyses of melanocortin-4 receptor mutations identified from patients with binge eating disorder and nonobese or obese subjects. J. Clin. Endocrinol. Metab. 90:5632-38
142. Adan RA, Hillebrand JJ, De Rijke C, Nijenhuis W, Vink T, et al. 2003. Melanocortin system and eating disorders. Ann. N.Y. Acad. Sci. 994:267-74
143. Adan RA, Vink T. 2001. Drug target discovery by pharmacogenetics: mutations in the melanocortin system and eating disorders. Eur. Neuropsychopharmacol. 11:483-90
144. Nijenhuis WA, Garner KM, van Rozen RJ, Adan RA. 2003. Poor cell surface expression of human melanocortin-4 receptor mutations associated with obesity. J. Biol. Chem. 278:22939-45
145. Govaerts C, Srinivasan S, Shapiro A, Zhang S, Picard F, et al. 2005. Obesity-associated mutations in the melanocortin 4 receptor provide novel insights into its function. Peptides 26:1909-19
146. Finlay BB, McFadden G. 2006. Anti-immunology: evasion of the host immune system by bacterial and viral pathogens. Cell 124:767-82
147. Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, et al. 2000. International Union of Pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol. Rev. 52:145-76
148. Vischer HF, Vink C, Smit MJ. 2006. A viral conspiracy: hijacking the chemokine system through virally encoded pirated chemokine receptors. Curr. Top. Microbiol. Immunol. 303:121-54
149. Cesarman E, Nador RG, Bai F, Bohenzky RA, Russo JJ, et al. 1996. Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in Kaposi's sarcoma and malignant lymphoma. J. Virol. 70:8218-23
150. Smit MJ, Vink C, Verzijl D, Casarosa P, Bruggeman CA, Leurs R. 2003. Virally encoded G protein-coupled receptors: targets for potentially innovative antiviral drug development. Curr. Drug. Targets 4:431-41
151. Yang TY, Chen SC, Leach MW, Manfra D, Homey B, et al. 2000. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J. Exp. Med. 191:445-54
152. Rosenkilde MM, Kledal TN, Holst PJ, Schwartz TW. 2000. Selective elimination of high constitutive activity or chemokine binding in the human herpesvirus 8 encoded seven transmembrane oncogene ORF74. J. Biol. Chem. 275:26309-15
153. Holst PJ, Rosenkilde MM, Manfra D, Chen SC, Wiekowski MT, et al. 2001. Tumorigenesis induced by the HHV8-encoded chemokine receptor requires ligand modulation of high constitutive activity. J. Clin. Invest. 108:1789-96
154. Sodhi A, Montaner S, Patel V, Gomez-Roman JJ, Li Y, et al. 2004. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc. Natl. Acad. Sci. USA 101:4821-26
155. Jensen KK, Manfra DJ, Grisotto MG, Martin AP, Vassileva G, et al. 2005. The human herpes virus 8-encoded chemokine receptor is required for angioproliferation in a murine model of Kaposi's sarcoma. J. Immunol. 174:3686-94
156. Grisotto MG, Garin A, Martin AP, Jensen KK, Chan P, et al. 2006. The human herpesvirus 8 chemokine receptor vGPCR triggers autonomous proliferation of endothelial cells. J. Clin. Invest. 116:1264-73
157. Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, et al. 2003. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 3:23-36
158. Montaner S, Sodhi A, Ramsdell AK, Martin D, HuJ, et al. 2006. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor as a therapeutic target for the treatment of Kaposi's sarcoma. Cancer Res. 66:168-74
159. Paulsen SJ, Rosenkilde MM, Eugen-Olsen J, Kledal TN. 2005. Epstein-Barr virus-encoded BILF1 is a constitutively active G protein-coupled receptor. J. Virol. 79:536-46
160. Beisser PS, Verzijl D, Gruijthuijsen YK, Beuken E, Smit MJ, et al. 2005. The Epstein-Barr virus BILF1 gene encodes a G protein-coupled receptor that inhibits phosphorylation of RNA-dependent protein kinase. J. Virol. 79:441-49
161. Casarosa P, Bakker RA, Verzijl D, Navis M, Timmerman H, et al. 2001. Constitutive signaling of the human cytomegalovirus-encoded chemokine receptor US28. J. Biol. Chem. 276:1133-37
162. Casarosa P, Gruijthuijsen YK, Michel D, Beisser PS, Holl J, et al. 2003. Constitutive signaling of the human cytomegalovirus-encoded receptor UL33 differs from that of its rat cytomegalovirus homolog R33 by promiscuous activation of G proteins of the Gq, Gi, and Gs classes. J. Biol. Chem. 278:50010-23
163. Minisini R, Tulone C, Luske A, Michel D, Mertens T, et al. 2003. Constitutive inositol phosphate formation in cytomegalovirus-infected human fibroblasts is due to expression of the chemokine receptor homologue pUS28. J. Virol. 77:4489-501
164. Streblow DN, Soderberg-Naucler C, Vieira J, Smith P, Wakabayashi E, et al. 1999. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell 99:511-20
165. Waldhoer M, Casarosa P, Rosenkilde MM, Smit MJ, Leurs R, et al. 2003. The carboxyl terminus of human cytomegalovirus-encoded 7 transmembrane receptor
166. Casarosa P, Menge WM, Minisini R, Otto C, van Heteren J, et al. 2003. Identification of the first nonpeptidergic inverse agonist for a constitutively active viral-encoded G protein-coupled receptor. J. Biol. Chem. 278:5172-78
167. Stassen FR, Vega-Cordova X, Vliegen I, Bruggeman CA. 2006. Immune activation following cytomegalovirus infection: more important than direct viral effects in cardiovascular disease? J. Clin. Virol. 35:349-53
168. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, et al. 2002. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 62:3347-50
169. Harkins L, Volk AL, Samanta M, Mikolaenko I, Britt WJ, et al. 2002. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 360:1557-63
170. Chen F, Castranova V, Shi X, Demers LM. 1999. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin. Chem. 45:7-17
171. Cinatl JJ, Vogel JU, Kotchetkov R, Wilhelm Doerr H. 2004. Oncomodulatory signals by regulatory proteins encoded by human cytomegalovirus: a novel role for viral infection in tumor progression. FEMS Microbiol. Rev. 28:59-77
172. Maussang D, Verzijl D, van Walsum M, Leurs R, Holl J, et al. 2006. Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis. Proc. Natl. Acad. Sci. USA 103:13068-73
173. Hulshof JW, Casarosa P, Menge WM, Kuusisto LM, van der Goot H, et al. 2005. Synthesis and structure-activity relationship of the first nonpeptidergic inverse agonists for the human cytomegalovirus encoded chemokine receptor US28. J. Med. Chem. 48:6461-71
174. Mannstadt M, Juppner H, Gardella TJ. 1999. Receptors for PTH and PTHrP: their biological importance and functional properties. Am. J. Physiol. Renal Physiol. 277:F665-75
175. Schipani E, Kruse K, Juppner H. 1995. A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 268:98-100
176. Brown EM, MacLeod RJ. 2001. Extracellular calcium sensing and extracellular calcium signaling. Physiol. Rev. 81:239-97
177. Pin JP, Galvez T, Prezeau L. 2003. Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol. Ther. 98:325-54
178. Hu J, Spiegel AM. 2003. Naturally occurring mutations of the extracellular Ca2+-sensing receptor: implications for its structure and function. Trends Endocrinol. Metab. 14:282-88
179. Pidasheva S, D'Souza-Li L, Canaff L, Cole DE, Hendy GN. 2004. CASRdb: calcium-sensing receptor locus-specific database for mutations causing familial (benign) hypocalciuric hypercalcemia, neonatal severe hyperparathyroidism, and autosomal dominant hypocalcemia. Hum. Mutat. 24:107-11
180. Zhao XM, Hauache O, Goldsmith PK, Collins R, Spiegel AM. 1999. A missense mutation in the seventh transmembrane domain constitutively activates the human Ca2+ receptor. FEBS Lett. 448:180-84
181. Watanabe S, Fukumoto S, Chang H, Takeuchi Y, Hasegawa Y, et al. 2002. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet 360:692-94
182. DeCamp DL, Thompson TM, de Sauvage FJ, Lerner MR. 2000. Smoothened activates Galphai-mediated signaling in frog melanophores. J. Biol. Chem. 275:26322-27
183. Taipale J, Cooper MK, Maiti T, Beachy PA. 2002. Patched acts catalytically to suppress the activity of Smoothened. Nature 418:892-97
184. Huang S, He J, Zhang X, Bian Y, Yang L, et al. 2006. Activation of the hedgehog pathway in human hepatocellular carcinomas. Carcinogenesis. 27:1334-40
185. Kayed H, Kleeff J, Keleg S, Guo J, Ketterer K, et al. 2004. Indian hedgehog signaling pathway: expression and regulation in pancreatic cancer. Int. J. Cancer 110:668-76
186. Ma X, Sheng T, Zhang Y, Zhang X, He J, et al. 2006. Hedgehog signaling is activated in subsets of esophageal cancers. Int. J. Cancer 118:139-48
187. Sheng T, Li C, Zhang X, Chi S, He N, et al. 2004. Activation of the hedgehog pathway in advanced prostate cancer. Mol. Cancer 3:29
188. Tabs S, Avci O. 2004. Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. Eur. J. Dermatol. 14:96-102
189. Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, et al. 2000. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 406:1005-9
190. Athar M, Li C, Tang X, Chi S, Zhang X, et al. 2004. Inhibition of Smoothened signaling prevents UV B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res. 64:7545-52
191. Tas S, Avci O. 2004. Rapid clearance of psoriatic skin lesions induced by topical cyclopamine. A preliminary proof of concept study. Dermatology 209:126-31
192. Chen JK, Taipale J, Young KE, Maiti T, Beachy PA. 2002. Small molecule modulation of Smoothened activity. Proc. Natl. Acad. Sci. USA 99:14071-76
193. Frank-Kamenetsky M, Zhang XM, Bottega S, Guicherit O, Wichterle H, et al. 2002. Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists. J. Biol. 1:10
194. Sinha S, Chen JK. 2006. Purmorphamine activates the Hedgehog pathway by targeting Smoothened. Nat. Chem. Biol. 2:29-30
195. Hubbell WL, Altenbach C, Hubbell CM, Khorana HG. 2003. Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. Adv. Protein. Chem. 63:243-90
196. Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, et al. 2005. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N. Engl. J. Med. 352:558-69
197. Nauta WT, Rekker RF, Harms AF. 1968. Proc. Int. Pharmacol. Meet., 3rd, 1966 7:305
198. Kraulis J. 1991. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structure. J. Appl. Cryst. 24:946-50
199. Merritt EA, Bacon DJ. 1997. Raster3D: photorealistic molecular graphics. Methods Enzymol. 277:505-24
200. Stenson PD, Ball EV, Mort M, Phillips AD, Shiel JA, et al. 2003. Human gene mutation database (HGMD): 2003 update. Hum. Mutat. 21:577-81